TSX up after index logs fresh record high close
Investing.com - Ideaya Biosciences (NASDAQ:IDYA) shares fell 14% on Tuesday despite the company presenting positive clinical updates across three programs during its R&D Day.
JMP Securities reiterated its Market Outperform rating on Ideaya with a $45.00 price target, noting the company shared encouraging data from its Phase 2 neoadjuvant UM brachytherapy study, DLL3 ADC Phase 1 data from Chinese partner Hengrui, and early safety and efficacy signals from MAT2Ai combined with Trodelvy in mUC. InvestingPro data shows analyst targets ranging from $27 to $74, with a strong buy consensus recommendation.
The stock decline appeared to reflect broader market concerns about the translatability of Chinese clinical data to Western patients, an issue that affected several biotechnology companies on Tuesday, including Summit Therapeutics, which fell 25%, and BioNTech, which dropped 9%.
JMP Securities maintained that Ideaya’s data was "excellent across the board," providing investors with "several opportunities to pay attention to" despite the negative market reaction.
The firm expects several important clinical program updates from Ideaya in the second half of 2025 and early 2026, supporting its maintained Market Outperform rating and $45 price target, which is derived from discounted cash flow analysis. According to InvestingPro’s Fair Value analysis, the stock appears slightly undervalued, with additional insights and 8 more ProTips available for subscribers.
In other recent news, IDEAYA Biosciences reported promising interim data from its Phase 1/2 trial combining IDE397 with Gilead’s Trodelvy for MTAP-deletion urothelial cancer, showing an overall response rate of 57% at a higher dosage. The company also announced encouraging results from a Phase 1 trial of IDE849, in partnership with Hengrui Pharma, for small cell lung cancer, with an 80% overall response rate. Additionally, IDEAYA released positive interim results from its Phase 2 OptimUM-09 trial for primary uveal melanoma, with 76% of patients achieving significant tumor shrinkage.
Citizens JMP raised its price target for IDEAYA Biosciences to $45, maintaining a Market Outperform rating, citing strong Phase 1 clinical data for IDE849. The IDE849 drug, presented at the World Conference on Lung Cancer, demonstrated a 77.1% overall response rate in second-line small cell lung cancer patients. IDEAYA’s collaborative efforts with Hengrui Pharma continue to yield significant clinical advancements. These developments highlight IDEAYA’s ongoing commitment to cancer treatment innovation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.